Study finds statin lowers heart attack risk in average cholesterol group
A Merck funded trial of 6,605 adults found lovastatin reduced heart attack and serious heart disease events by 37 percent over five years compared with a placebo. Researchers caution debates on cost, long term safety, and expanding use beyond high risk patients.
MENTIONED IN THIS ARTICLE
Merck & Co
Merck
Journal of the American Medical Association
American Heart Association
Jeffrey Isner
St. Elizabeth's Hospital
Boston
Antonio M. Gotto Jr
Welll Medical College
Cornell University
Alan Garber
Center For Primary Care and Outcomes Research
Stanford University
Garber
National Heart, Lung, and Blood Institute
Gotto
Also Mentioned on This Page
Nlat
Bud Poliquin
Albany
Erik Kriss
Sean Kirst
Gina Kolata
New York Times News Service
Claude Lenfant
Basis
Restau
New York
York
MHC
New UK
Tsinese Ap
Gonouceen
Marie New Fork
Satria